Targets › CBL
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2026.
E3 ubiquitin-protein ligase that acts as a negative regulator of many signaling pathways by mediating ubiquitination of cell surface receptors. Accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. (UniProt, P22681)
Open in Phaseline: the race on CBL, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| HotSpot Therapeutics | HST-1011 CBL-B inhibitor | CBL | Phase 1 | Solid Tumor, Adult | Dec 2026 |
Solid Tumor, Adult (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.